GSK To Add Antiretroviral Drug To Medicines Patent Pool

Reuters: GSK’s ViiV unit adds new HIV drug to AIDS patent pool
“GlaxoSmithKline’s AIDS drugs business is to add one of its latest HIV medicines to a patent pool — cutting its future price for developing countries and pooling intellectual property rights. ViiV Healthcare, which is majority owned by the British drugmaker, said the agreement covered dolutegravir, a new antiretroviral medicine, for use in both adults and children with the human immunodeficiency virus (HIV) that causes AIDS…” (Kelland, 4/1).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.